Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? by Pompili, Maurizio et al.
© 2008 Pompili et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2008:4(1) 247–255 247
ORIGINAL RESEARCH
Suicide risk in depression and bipolar 
disorder: Do impulsiveness-aggressiveness 
and pharmacotherapy predict suicidal intent?
Maurizio Pompili1,2
Marco Innamorati3
Michele Raja4
Ilaria Falcone2
Giuseppe Ducci5
Gloria Angeletti2
David Lester6
Paolo Girardi2
Roberto Tatarelli2
Eleonora De Pisa2
1McLean Hospital, Harvard 
Medical School, Boston, MA, 
USA; 2Department of Psychiatry, 
Sant’Andrea Hospital, “Sapienza” 
University of Rome, Italy; 3Università 
Europea di Roma, Italy; 4Diagnostic 
and Therapeutic Psychiatric Services, 
Department of Mental Health, 
Santo Spirito Hospital, Rome, 
Italy; 5Diagnostic and Therapeutic 
Psychiatric Services, Department 
of Mental Health, San Filippo Neri 
Hospital, Rome, Italy; 6Center for the 
Study of Suicide, Blackwood, NJ, USA
Correspondence: Maurizio Pompili
Sant’Andrea Hospital, Dept. of Psychiatry, 
Via di Grottarossa 1035, 0189 Roma, Italy
Email maurizio.pompili@uniroma1.it or 
mpompili@mclean.harvard.edu
Abstract: The aims of the present study were to examine clinical, personality, and sociodemo-
graphic predictors of suicide risk in a sample of inpatients affected by major affective disorders. 
The participants were 74 inpatients affected by major depressive disorder or bipolar disorder-I. 
Patients completed a semi-structured interview, the Beck Hopelessness Scale, the Aggression 
Questionnaire, the Barratt Impulsiveness Scale, and the Hamilton scales for depression and 
anxiety. Over 52% of the patients were high suicide risks. Those at risk reported more severe 
depressive-anxious symptomatology, more impulsivity and more hostility. Impulsivity, the use 
of antidepressants, anxiety/somatization, and the use of mood stabilizers (a negative predictor) 
resulted in accurate predicting of suicide intent. Impulsivity and antidepressant use were the stron-
gest predictors even after controlling for several sociodemographic and clinical variables.
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Introduction
Suicide is a major worldwide public health problem. Nearly one million lives are lost 
each year to suicide, and between 3%–5% of adults make at least one suicide attempt 
at some point in their life (Kessler et al 1999; Weissman et al 1999; Szadoczky et al 
2000).
The relationship between suicide and psychiatric disorders is an important issue. 
More than two-thirds of suicide completers and suicide attempters have (mostly 
untreated) major depressive episodes at the time of the suicidal act (Coryell and Young 
2005). People with major affective disorders (MAD), that is, unipolar major depressive 
disorder (MDD) and bipolar disorder type I and type II (BPD-I, BPD-II) are highly 
vulnerable to suicidal behavior. It is estimated that individuals with BPD are 30 times 
more likely to attempt suicide than those with no psychiatric disorder (Chen and Dilsaver 
1996; Kessler et al 1999; Potash et al 2000). Suicide behavior in major affective disor-
ders is also characterized by high lethality (Baldessarini et al 2006c), as indicated by the 
ratio of estimated rates of attempted suicide to completed suicide. Between 6%–20% of 
bipolar patients die by suicide compared with 25%–56% attempting suicide (Goodwin 
and Jamison 1990; Harris and Barraclough 1997; Inskip et al 1998).
However, as Hendin (1986) pointed out, “the vast majority of depressed, 
schizophrenic, alcoholic or organically psychotic patients do not commit or even 
attempt suicide”. Hendin went on to suggest that “the interest in classifying populations 
of suicidal patients by their psychiatric diagnoses is being supplemented by an interest in 
understanding what makes a minority of patients within any given diagnostic category 
suicidal while the majority are not suicidal”.
The search for suicide risk factors, variables which indicate an increased likelihood 
for suicide, independent of diagnosis, has been espoused by a number of researchers and Neuropsychiatric Disease and Treatment 2008:4(1) 248
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clinicians. Most studies have evaluated short-term risk factors 
for suicidal behavior, such as suicidal ideation and recent 
suicide attempt, the major precursors and the most powerful 
predictors of attempted and completed suicide (Coryell and 
Young 2005; Hawton et al 2005; Rihmer 2007).
However, a single risk factor is not sufﬁ  cient to predict 
suicide (Bongar 2000). Despite intensive efforts, effective 
prediction and prevention strategies have remained elusive, 
suggesting that our understanding of the interplay of fac-
tors that increase the risk of suicide remains incomplete. 
Prediction of suicidal behavior in the long-term and lists of 
personality predictors are also important and challenging 
tasks for the clinician (Stelmachers 1995).
Impulsivity/aggression has been reported to be related to 
suicidal behavior in several studies (Weissman et al 1973; 
Dumais et al 2005; Galfalvy et al 2006). For example, 
Mann and colleagues (1999) proposed a stress-diathesis 
model of suicidal behavior. Impulsivity, related to genetic 
predisposition and dysfunctions of the prefrontal cortex, is 
part of the diathesis predisposing individuals with suicidal 
ideation to act upon their impulse. Higher aggression may 
also contribute to the increased lethality of suicide attempts 
(Baca-Garcia et al 2006).
In 2004, the United States Food and Drug Administration 
(FDA) warned of suicidality in children and adolescents 
after antidepressant treatment (FDA 2004). However, 
several studies have failed to produce evidence of a 
signiﬁ  cant effect of antidepressants on suicide risk (Simon 
et al 2006; Sondergard et al 2006). For example, Tiihonen 
and colleagues (2006), in a national cohort study of suicidal 
subjects who had used antidepressants, found that the 
current use of any antidepressant was associated with a 
markedly increased risk of attempting suicide and, at the 
same time, with a markedly decreased risk of completed 
suicide. According to this study, the lower overall mortality 
was attributable to a decrease in cardiovascular and 
cerebrovascular-related deaths during selective serotonin 
reuptake inhibitor use.
The literature supports the efﬁ  cacy of long-term lithium 
treatment for suicidal patients (Thies Flechtner et al 1996; 
Baldessarini et al 2003, 2006b, 2006d), and lithium is 
considered to be the ﬁ  rst-line treatment for reducing the risk 
of suicide (Grunze et al 2002) while there is weaker evidence 
for the usefulness of anticonvulsivants in preventing suicide 
(Thies Flechtner et al 1996; Goodwin et al 2003). There 
is also evidence that atypical antipsychotics, particularly 
clozapine, may contribute to a reduction in suicidality in 
patients with affective disorders (Anonymous 1998).
Thus, impulsive/aggression may be a powerful risk factor 
for suicidal behavior. It may play a role as a diathesis predis-
posing individuals with acute disorders (stressors) to act upon 
their suicidal ideation. Pharmacotherapy may play a strong 
role in reducing suicidal intent, via different mechanisms, 
for example, either reducing impulsivity, suicide ideation, 
or hopelessness.
The aims of the present study were to examine the single 
role of impulsivity/aggression on increasing suicidal intent, 
and the role of several pharmacological agents in reducing 
suicidal intent in a sample of MAD inpatients. The next 
step was to examine the multivariate relationship between 
impulsivity/aggression, pharmacotherapy and hopelessness, 
controlling for potential confounders.
Although, some authors assessed impulsivity/aggression 
via lifetime aggressive behavior, we preferred to assess 
stable personality-like traits and both covert and overt 
components. Impulsivity is essentially related to the control 
of thoughts and behavior, and to the ability to observe and 
conform to social norms in society. Trait aggression focuses 
on the intent, the means of expression, and the affective 
factors that inﬂ  uence aggression. Thus, trait aggression is 
both a feeling of hostility that arouses thoughts of attacking 
others, the disposition to act out one’s hostility, and violent 
or deliberately unfriendly behavior.
Suicidal intent was measured via hopelessness. 
Hopelessness is a cognitive trait associated with suicide, 
leading suicidal patients to believe that suicide is the only 
feasible strategy for dealing with their seemingly insoluble 
problems. The relationship between hopelessness and suicidal 
intent has been supported by empirical research (Bedrosian 
and Beck 1979; Wetzel et al 1980; Chandrasekaran and 
Gnanaselane 2005). Beck and colleagues (1985, 1990) 
carried out two prospective study of inpatient and outpatient 
samples. The authors found that hopelessness scores were 
related signiﬁ  cantly to eventual completed suicide. A cutoff 
score of 9 or above identiﬁ  ed most of the patients who 
eventually committed suicide. The high-risk group identiﬁ  ed 
in the latter study was 11 times more likely to commit suicide 
than the rest of the outpatients. Thus, hopelessness may be 
used as an indicator of suicide potential (Table 1).
Methods and materials
Participants
Participants were 74 inpatients (37 men, 37 women) 
consecutively admitted to three psychiatric acute wards 
located in Rome. The patients admitted showed either Neuropsychiatric Disease and Treatment 2008:4(1) 249
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psychotic-like symptoms, suicidal behavior, or aggressive 
behavior. Inclusive criteria were diagnosis of a DSM-IV-TR 
major affective disorder (unipolar major depressive disorder 
or bipolar disorder type I, currently experiencing a depressive 
episode). Exclusion criteria were diagnosis of mood disorders 
not listed above (eg, cyclothymia, bipolar disorder type II, 
etc), diagnosis of dementia or delirium, current or past history 
of schizophrenia and schizoaffective disorder, illiteracy or 
any condition that made the subject unable to complete the 
assessment or give informed consent. The average ages 
for participants were: women 44.32 years (SD = 13.01) 
and men 39.76 years (SD = 12.39). At intake, the patients 
were assessed for psychiatric diagnoses and the scales were 
administered. A consultant psychiatrist assessed MAD 
diagnosis by structured interview, evaluating the differential 
diagnosis using DSM-IV diagnostic algorithms and clinical 
judgement. The clinical and demographic characteristics 
of the patients are listed in Table 2. Twenty-eight patients 
were diagnosed with unipolar MDD and 46 patients were 
diagnosed with BPD-I.
Subjects participated voluntarily in the study, and each 
subject provided written informed consent. The study pro-
tocol received ethics approval from the local research ethics 
review board. Patients were interviewed on average ﬁ  ve 
days after intake
Instruments
Patients completed the Mini International Neuropsychiat-
ric Interview (MINI) Italian Version 5.0.0 (Sheehan et al 
1998), the Beck Hopelessness Scale (BHS), the Aggres-
sion Questionnaire (AQ) (Buss and Perry 1992), the Bar-
ratt Impulsiveness Scale (BIS-11) (Patton et al 1995), the 
Hamilton Rating Scale for Depression (HAM-D) (Hamilton 
1960, 1967) and the Hamilton scale for Anxiety (HAM-A) 
(Hamilton 1959).
The BHS is a 20-item scale for measuring the cognitive 
component of the syndrome of depression. This scale assesses 
three major aspects of hopelessness: feelings about the future, 
loss of motivation, and expectations.
The AQ contains 29 self-report Likert-type items (eg, 
“I tell my friends openly when I disagree with them”, “Given 
enough provocation, I may hit another person”) assessing 
cognitive, affective, and behavioral components of this 
domain. Subscales include Hostility (ie, hostile cognition), 
Anger (ie, hostile affect), Physical Aggression, and Verbal 
Aggression.
The BIS-11 is a 30-item questionnaire (eg, “I act on 
impulse”, “I plan tasks carefully”) that has been validated 
in several different populations. The BIS-11 includes three 
subscales labeled attentional, nonplanning, and motor (Patton 
et al 1995). These three subscales have been replicated 
in an Italian population (Fossati et al 2001). However, 
subfactor item loadings differed between the English and 
Italian versions: the ﬁ  rst factor (F1) combined attention and 
motor impulsiveness, the second factor (F2) was deﬁ  ned by 
perseverance and lack of delay in obtaining gratiﬁ  cation, 
while the third Factor (F3) reproduced the original factor 
nonplanning impulsiveness.
Results
Patients reported high scores on hopelessness, and over 52% 
evidenced scores higher than 9, indicating high suicide intent 
(see Table 2). No differences were found by sex or diagnosis 
(see Tables 2 and 3). Twenty-seven people (36.5%) reported a 
history of suicide attempts, and 16 (21.6%) reported multiple 
suicide attempts. Female patients were more likely to have 
attempted suicide than male patients, while men reported 
more physical aggressiveness. No differences were revealed 
between MDD and BPD patients. Thus, we may consider 
inpatients with MAD to be a group at high risk of suicide 
behavior, with the female patients at higher risk.
The analysis indicated differences between patients with 
the two diagnoses (see Table 3). Patients with major depres-
sive disorder reported more depression, somatization and 
symptoms of anxiety, retardation and diurnal variation.
When considering the differences between the group 
with high risk of suicide and the group with low risk, as 
measured by the BHS, several differences were identiﬁ  ed. 
The patients at risk reported more severe depressive 
and anxious symptomatology, and more impulsivity 
Table 1 Risk factors for suicide in bipolar disorder (adapted 
from Baldessarini et al 2006a)
Early in the course of illness
Younger age 
Depressive, mixed dysphoric-irritable states
Caucasian ethnicity
Being unmarried
Previous depression
Previous dysphoric-agitated states
Hopelessness
Previous suicide attempts
Substance or alcohol abuse
Impulsivity
Stressful life events (deaths, divorce, separations, scandals, etc)
Suicidal ideation
Limited access to support or clinical servicesNeuropsychiatric Disease and Treatment 2008:4(1) 250
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Table 2 Socio-demographic and clinical variables broken down by sex
  Total   Men   Women   Test   Effect 
Variables (N  = 74)  (N = 37)  (N = 37)  (Sig.)  sizes
Age – M (SD)  42.04 (12.83)  39.76 (12.39)  44.32 (13.01)  1.55a (0.13) 
MDD – N (%)  28 (37.8)  12 (32.4)  16 (43.2)  0.24b 
BPD – N (%)  46 (62.2)  25 (67.6)  21 (56.8)   
Suicide attempts – N (%)  27 (36.5)  9 (24.3)  18 (48.6)  0.03b  Φ = −0.25
Multiple suicide   16 (21.6)  6 (16.2)  10 (27.0)  0.20b 
attempts – N (%)         
BIS – M (SD)  67.68 (13.92)  67.16 (12.03)  68.19 (15.74)  0.32a (0.75) 
F1 – M (SD)  21.81 (6.60)  21.86 (5.95)  21.76 (7.26)  −0.07a (0.94) 
F2 – M (SD)  25.61 (5.62)  25.68 (4.87)  25.54 (6.34)  −0.10a (0.92) 
F3 – M (SD)  20.26 (5.18)  19.62 (5.13)  20.89 (5.23)  1.055a (0.30) 
AQ – M (SD)  72.35 (17.45)  74.78 (17.82)  69.92 (16.97)  −1.20a (0.23) 
PA – M (SD)  18.50 (7.67)  21.11 (8.71)  15.89 (5.44)  −3.09a (0.003)  D = 0.72
VA – M (SD)  13.86 (4.14)  13.76 (4.22)  13.97 (4.11)  0.22a (0.82) 
A – M (SD)  17.35 (5.66)  17.32 (5.46)  17.38 (5.92)  0.04a (0.97) 
H – M (SD)  22.64 (6.59)  22.59 (6.95)  22.68 (6.30)  0.05a (0.96) 
BHS – M (SD)  9.53 (5.34)  9.70 (5.45)  9.35 (5.29)  −0.28a (0.78) 
BHS   9 – N (%)  39 (52.7)  20 (54.1)  19 (51.4)  0.50b 
Feelings about the   1.81 (1.63)  1.81 (1.65)  1.81 (1.63)  0.00a (1.00) 
future – M (SD)         
Loss of motivation – M   3.62 (2.30)  3.68 (2.38)  3.57 (2.26)  −0.20a (0.84) 
(SD)       
Expectations – M   3.28 (1.57)  3.41 (1.59)  3.16 (1.56)  −0.67a (0.51) 
(SD)       
HAM-A – M (SD)  19.03 (8.06)  20.05 (8.66)  18.00 (7.40)  −1.01a (0.28) 
Somatic anxiety – M   6.84 (4.87)  7.70 (5.42)  5.97 (4.14)  −1.54a (0.13) 
(SD)       
Psychic anxiety – M   12.19 (4.81)  12.35 (4.84)  12.03 (4.85)  −0.29a (0.77) 
(SD)       
HAM-D – M (SD)  20.59 (7.29)  21.19 (6.70)  20.00 (7.88)  −0.70a (0.49) 
Anxiety/somatization – M   6.73 (3.35)  6.62 (3.23)  6.84 (3.51)  0.28a (0.78) 
(SD)       
Weight loss – M   0.77 (1.15)  0.84 (1.17)  0.70 (1.15)  −0.50a (0.62) 
(SD)       
Cognitive disturbance –   5.80 (2.95)  5.51 (3.01)  6.08 (2.91)  0.83a (0.41) 
M  (SD)       
Diurnal variation –   1.00 (1.40)  1.14 (1.48)  0.86 (1.34)  −0.83a (0.41) 
M  (SD)       
Retardation – M   6.24 (3.36)  7.08 (2.85)  5.41 (3.66)  −2.20a (0.03)  D = 0.51
(SD)       
Sleep disturbance – M  2.54 (1.41)  2.76 (1.517)  2.32 (1.27)  −1.33a (0.19) 
(SD)       
Notes: a – t-test; b – 1-FET.
Abbreviations: MDD, major depressive disorder; BPD, bipolar disorder; BIS, Barratt Impulsiveness Scale; AQ, Aggression Questionnaire; PA, Physical Aggression; VA, Verbal 
Aggression; A, Anger; H, Hostility; BHS, Beck Hopelessness Scale; HAM-D, Hamilton scale for Depression; HAM-A, Hamilton scale for Anxiety; 1-FET, one-way Fisher exact 
test; M, mean; SD, standard deviation; D, Cohen’s D index; Φ, Phi coefﬁ  cient.
and hostility. Thus, MAD patients at risk of suicide 
experience an increasing burden of depressive and anxiety 
symptoms and hostility in their relationships and act more 
impulsively.
The differences reported were reﬂ  ected in the therapy. 
More antidepressants (sertraline 50 mg/daily, parox-
etine 20 mg/daily, fluoxetine 20 mg/daily) had been 
prescribed to patients at risk for suicide, but fewer 
mood stabilizers (average doses: lithium 900 mg/daily, 
lamotrigine 200 mg/daily, carbamazepine 1300 mg/daily) 
and antipsychotics (olanzapine 20 mg/daily, quetiapine 
700 mg/daily). There was a slight tendency for the high-risk 
patients to report more cognitive disturbances.
To identify the best predictors of the BHS total score, 
sociodemographic and clinical variables were entered as 
predictors in a multiple regression model (see Table 4). 
In the ﬁ  rst step, the best predictor was only the BIS, and 
the model explained 31% of the variability of the BHS 
scores. The second step added the use of antidepressants 
as a predictor, with the model explaining another 13% Neuropsychiatric Disease and Treatment 2008:4(1) 251
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of the BHS variability. The third step added anxiety/
somatization as predictor (with an additional 6% of the 
variability explained). The last step added the use of mood 
stabilizers as negative predictor, that is, as a protective 
factor. The four predictors explained 50% of the variance 
in BHS scores.
To verify if pharmacotherapy and impulsiveness/
aggression were strong predictors even after controlling 
for diagnosis, depression and anxiety, and demographic 
variables, we performed a hierarchical multiple regression 
analysis (not reported in a table). In the ﬁ  rst block, we 
introduced the variables to be controlled and in the 
second block we introduced the BIS, the AQ, and the 
pharmacotherapy variables. This resulted in a signiﬁ  cant 
model explaining nearly 47% of the variance of BHS scores 
(F (13.60) = 5.97; p = 0.00; R2 change = 0.37; F change 
(6.60) = 7.70; p = 0.00). The BIS scores (Beta std. = 0.58; 
t = 5.66; p = 0.00) and antidepressant use (Beta std. = 
0.34; t = 2.96; p = 0.004) were conﬁ  rmed to be strong 
predictors.
Discussion
Our results are consistent with the view that people with 
MAD are highly vulnerable to suicidal behavior, and the 
women were the group were more likely to have attempted 
suicide than were the men. This is also consistent with the 
study by Schneider and colleagues (2001) who, analyzing 
mortality data from a prospective study of 354 outpatients 
Table 3 Sociodemographic and clinical variables broken down by diagnosis and suicide risk
Variables
MDD BPD Test (Sig.) Effect 
sizes
No risk of 
suicide
High risk of 
suicide
Test (Sig.) Effect 
sizes
Age – M (SD) 45.86 (15.25) 39.72 (10.62) 1.87a (0.07) 37.23 (10.14) 46.36 (13.55) –3.25a (0.002) D = –0.76
BHS – M (SD) 10.43 (4.93) 8.98 (5.55) 1.14a (0.26) - - -
BHS   9 – N (%) 18 (46.2) 21 (53.8) 0.09b ---
Feelings about the future – M (SD) 2.11 (1.64) 1.63 (1.61) 1.23a (0.22) - - -
Loss of motivation – M (SD) 3.79 (2.33) 3.52 (2.31) 0.48a (0.64) - - -
Expectations – M (SD) 3.54 (1.35) 3.13 (1.68) 1.08a (0.28) - - -
HAM-A – M (SD) 20.96 (9.15) 17.85 (7.18) 1.63a (0.11) 16.31 (7.92) 21.46 (7.48) −2.88a (0.01) D = −0.67
Somatic anxiety – M (SD) 6.89 (5.51) 6.80 (4.49) 0.08a (0.94) 6.14 (4.70) 7.46 (4.99) −1.17a (0.25)
Psychic anxiety – M (SD) 14.07 (4.91) 11.04 (4.42) 2.74a (0.01) D = 0.65 10.17 (4.36) 14.00 (4.51) −3.70a (0.000) D = −0.86
HAM-D – M (SD) 23.57 (7.14) 18.78 (6.84) 2.87a (0.01) D = 0.69 16.71 (7.06) 24.08 (5.58) −5.00a (0.000) D = −1.16
Anxiety/somatization – M (SD) 7.89 (3.34) 6.02 (3.19) 2.41a (0.02) D = 0.57 4.89 (2.92) 8.38 (2.83) −5.24a (0.000) D = −1.22
Weight loss – M (SD) 0.68 (1.19) 0.83 (1.14) −0.53a (0.60) 0.60 (1.04) 0.92 (1.24) −1.21a (0.23)
Cognitive disturbance – M (SD) 6.14 (2.65) 5.59 (3.13) 0.78a (0.44) 5.40 (3.10) 6.15 (2.81) −1.10a (0.28)
Diurnal variation – M (SD) 1.46 (1.50) 0.72 (1.28) 2.19a (0.03) D = 0.54 1.06 (1.47) 0.95 (1.36) 0.33a (0.74)
Retardation – M (SD) 7.93 (2.93) 5.22 (3.22) 3.63a (0.001) D = 0.88 4.63 (3.30) 7.69 (2.73) −4.37a (0.000) D = −1.01
Sleep disturbance – M (SD) 2.46 (1.29) 2.59 (1.48) −0.36a (0.72) 2.49 (1.48) 2.59 (1.35) –0.32a (0.75)
BIS – M (SD) 68.71 (12.57) 67.04 (14.78) 0.50a (0.62) 60.54 (10.60) 74.08 (13.52) −4.75a (0.000) D = −1.11
F1 – M (SD) 22.21 (6.70) 21.57 (6.60) 0.41a (0.68) 18.51 (4.91) 24.77 (6.56) −4.60a (0.000) D = −1.08
F2 – M (SD) 25.29 (5.17) 25.80 (5.92) −0.38a (0.70) 24.11 (4.79) 26.95 (6.01) −2.23a (0.03) D = −0.52
F3 – M (SD) 21.21 (4.99) 19.67 (5.27) 1.24a (0.22) 17.91 (4.96) 22.36 (4.48) −4.05a (0.000) D = −0.94
AQ – M (SD) 71.07 (18.81) 73.13 (16.74) −0.49a (0.63) 70.40 (18.57) 74.10 (16.43) −0.91a (0.37)
PA – M (SD) 17.89 (7.56) 18.87 (7.80) −0.53a (0.60) 19.09 (8.50) 17.97 (6.92) 0.62a (0.54)
VA – M (SD) 13.93 (4.36) 13.83 (4.05) 0.10a (0.92) 14.23 (4.02) 13.54 (4.27) 0.71a (0.48)
A – M (SD) 17.07 (5.45) 17.52 (5.83) −0.33a (0.74) 16.77 (5.94) 17.87 (5.42) −0.83a (0.41)
H – M (SD) 22.18 (6.66) 22.91 (6.61) −0.46a (0.65) 20.31 (6.07) 24.72 (6.41) −3.03a (0.003) D = −0.71
Suicide attempts – N (%) 10 (35.7) 17 (37.0) 0.56b 11 (31.4) 16 (41.0) 0.27b
Multiple suicide attempts – N (%) 6 (21.4) 10 (21.7) 0.61b 8 (22.9) 8 (20.5) 0.51a
Mood stabilizer – N (%) 22 (78.6) 41 (89.1) 0.18b 33 (94.3) 30 (76.9) 0.04b Φ = −0.24
Antidepressants – N (%) 12 (57.1) 3 (6.5) 0.000b Φ = −0.44 3 (8.6) 12 (30.8) 0.02b Φ = 0.28
Antipsychotics – N (%) 20 (71.4) 43 (93.5) 0.01b Φ = 0.30 34 (97.1) 29 (74.4) 0.006b Φ = −0.32
Anxiolytics – N (%) 11 (39.3) 10 (21.7) 0.09b 8 (22.9) 13 (33.3) 0.23b
Notes: at-test; b1-FET.
Abbreviations: MDD, major depressive disorder; BPD, bipolar disorder; BIS, Barratt Impulsiveness Scale; AQ, Aggression Questionnaire; PA, Physical Aggression; VA, Verbal 
Aggression; A, Anger; H, Hostility; BHS, Beck Hopelessness Scale; HAM-D, Hamilton scale for Depression; HAM-A, Hamilton scale for Anxiety; 1-FET, one-way Fisher exact 
test; M, mean; SD, standard deviation; D, Cohen’s D index; Φ, Phi coefﬁ  cient.Neuropsychiatric Disease and Treatment 2008:4(1) 252
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with affective disorders during a follow-up period of 5 years, 
observed nearly three times (SMR 2.9) the number of deaths 
expected on the basis of age- and sex-standardized reference 
population rates. Death from unnatural causes was 28.8 
times higher than expected. Women with affective disorders 
had a very high risk of dying from unnatural causes (SMR 
47.1). It seems that dysregulation of emotion follows dif-
ferent patterns of externalization/internalization in women 
and men with MAD. In stress-provoking situations, women 
are more likely to attempt suicide, while men report more 
external physical aggressiveness. Given the high risk of 
completed suicide in those patients suffering from major 
affective disorders and judged to be at high risk of suicide, 
it is crucial to perform a comprehensive assessment of 
suicide. Lester (1993) performed a meta-analysis of studies 
of suicidal behavior in patients with bipolar and unipolar 
affective disorders and found two possible trends: an excess 
of subsequent completed suicide in unipolar patients and an 
excess of subsequent attempted suicide in bipolar patients.
Our results indicated that impulsivity may be a strong 
predictor for suicide intent. MAD patients with problems of 
impulse control are at higher risk for suicide. Impulsivity was 
able to predict suicide even when controlling for diagnosis, 
anxiety and depression severity, and sociodemographic 
variables. Those variables were identiﬁ  ed as important risk 
factors for suicide by the US Surgeon General in the 1999 
document entitled “Call to action to prevent suicide”, a 
milestone for the dissemination of warnings to mental health 
professionals and general population alike (US Public Health 
Service 1999). Moreover, Dumais and colleagues (2005) 
found that impulsive-aggressive personality disorders and 
alcohol abuse/dependence were two independent predictors 
of suicide in major depression, and impulsive and aggressive 
behaviors seem to underlie these risk factors.
The analysis indicated differences in the drug therapy 
between patients at risk of suicide and patients without 
risk. Patients reporting more hopelessness are more likely 
to have been prescribed antidepressants (SSRI) and less 
likely to have been prescribed mood stabilizers (lithium, 
carbamazepine, lamotrigine) and antipsychotics (olanzap-
ine, quetiapine), the effect sizes of this difference being 
low/moderate. This might be due to the strong relationship 
between depression and hopelessness; however, suicide risk 
may be understood as constriction, tunneling, or focusing 
or narrowing the range of options usually available to an 
individual’s consciousness, when the individual cannot 
see any way out and therefore loses any positive expecta-
tion about the future, which leads to a hopeless feeling 
regardless of diagnosis. The fact that those experiencing 
hopelessness were prescribed more antidepressants should 
be viewed with caution. In fact, evidence emerging from 
clinical practice is suggestive that mood stabilizers can 
decrease the feelings of anguish and despair that are often 
associated with hopelessness both in unipolar and bipolar 
patients. Moreover, such drugs reduce the agitation com-
ponents of depressive-dysphoric states which often are 
correlated with impulsiveness and aggression and often 
found in suicidal crisis.
Table 4 Multiple regression (Stepwise)
Criterion: BHS
Step Predictors Beta Std. t Sig. Multicollinearity tolerance
1 BIS 0.56 5.76 0.00 1.00
2 BIS 0.60 6.79 0.00 0.99
Antidepressants 0.36 4.08 0.00 0.99
3 BIS 0.53 5.88 0.00 0.89
Antidepressants 0.30 3.48 0.001 0.93
Anxiety/somatization 0.26 2.86 0.01 0.87
4 BIS
Antidepressants
Anxiety/somatization
Mood stabiliser
0.51
0.23
0.28
−0.18
5.75
2.54
3.12
−2.03
0.00
0.01
0.003
0.05
0.88
0.80
0.86
0.86
Model Adjusted R2 F Sig. R2 change F change Sig. F change
1 0.31 33.16 0.00 0.32 33.16 0.00
2 0.43 28.50 0.00 0.13 16.64 0.00
3 0.48 23.64 0.00 0.06 8.16 0.01
4 0.50 19.54 0.00 0.03 4.10 0.05
Abbreviations: BHS, Beck Hopelessness Scale; BIS, Barratt Impulsiveness Scale.Neuropsychiatric Disease and Treatment 2008:4(1) 253
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Baldessarini and colleagues (2006d) suggested that the 
antisuicidal properties of lithium in bipolar disorder may act 
upon these components. Moreover, lithium has proven to 
be the best antisuicidal treatment even in major depression 
(Guzzetta et al 2007). However, we had no access to medical 
records regarding past pharmacotherapy in our patients, and 
we cannot know if any causal relationship exists between the 
variables. This could be important because there is growing 
evidence for suicidal risk reduction with long-term lithium 
maintenance (Thies Flechtner et al 1996; Baldessarini et al 
2003, 2006d).
Inconsistent with data reported elsewhere (Fawcett et al 
1990), neither a history of previous suicide attempts nor 
psychic anxiety was able to predict suicide risk in our sample 
of MAD patients. On the contrary, we found that the somatic 
symptomatology of anxiety predicts suicide risk.
Lastly, pharmacotherapy was a strong predictor of 
suicide risk. It was the strongest predictor of suicide risk 
even after controlling for diagnosis, anxiety and depression 
severity, and sociodemographic variables. Mood stabilizer 
use as whole (considering both lithium and anticonvulsants) 
was the only protective factor for suicide risk in our analysis, 
but only before controlling for clinical and sociodemo-
graphic variables. This latter result could be explained by 
our inclusion of both lithium and anticonvulsants as mood 
stabilizers.
The predictive power of antidepressant use is relevant to 
the ongoing debate about the potential increase in suicidal 
risk among patients being treated with antidepressant drugs 
(FDA 2004; Baldessarini et al 2006c, 2006b; Simon et al 
2006; Sondergard et al 2006). Several studies have failed to 
produce evidence of a signiﬁ  cant effect of antidepressants on 
suicide risk (Simon et al 2006; Sondergard et al 2006).
In March 2004, the US FDA issued a public health 
advisory regarding worsening depression and suicidality 
in pediatric and adult patients being treated with several 
antidepressants (FDA 2004). Although, the question is 
still controversial (Simon et al 2006), Kahn and colleagues 
(Khan et al 2000) provided data on suicides and attempts 
extracted from controlled premarketing trials submitted 
to the FDA for several modern antidepressants, including 
SSRIs (paroxetine, sertraline) and other agents (mirtazapine, 
nefazodone), the older, standard drugs, and placebos. 
These pooled trials yielded relevant data for large numbers 
of subjects (2,709–5,921), but for only brief exposures 
averaging 3–7 months. Minor differences were found in 
suicidal risk among the non-SSRI agents (3.46%/year) and 
placebos (3.06%/year), with a somewhat higher risk for 
SSRIs (6.75%/year). As suggested by Baldessarini collegues 
(2006b), suicidal ideation, but usually not suicidal behavior, 
can been reduced with antidepressant treatment. These 
considerations suggest that, suicidal acts require more than 
depressed mood and thoughts of death. The utility of the 
ﬁ  ndings of the meta-analysis as a basis for sound clinical 
practice and regulatory policy is limited by the low levels of 
“suicidal events” reported, even lower frequency of actual 
suicidal behaviors, and variable outcomes across trials and 
treatments (Baldessarini et al 2006b).
Although the use of antidepressants seems not to be asso-
ciated with an elevated suicide risk, there are circumstances 
when it is compulsory not to use antidepressants. Administra-
tion of antidepressants may lead to a switch from depression 
to mania or increase the irritable component of the disorder, a 
condition often associated with high suicide risk. In contrast, 
when high-voltage manic individuals slow down and their 
mood switches into depression, the reduced impetuousness 
and happiness can indicate an elevated suicide risk.
Impulsivity and aggression may be particularly important 
for both the risk and the timing of suicidal acts and may help 
to account for the striking disparity between the effectiveness 
of lithium in reducing suicidal risk and the lack of evidence of 
such an effect for antidepressants in the treatment of unipolar 
or bipolar major depression (Khan et al 2000, 2003; Jick et al 
2004; Baldessarini 2005; Baldessarini et al 2005, 2006b; 
Baldessarini and Tarazi 2005; Gunnell et al 2005; Martinez 
et al 2005).
The role of mood-stabilizers appears to be the better 
remedy for the violent agitation that may precede suicide 
in bipolar disorders. Especially in mixed states, which may 
occur as a transitional condition when depression escalates 
into mania, the correct dosage of a mood stabilizer may 
determine whether or not an individual develops a high 
risk of suicide. Volatile and erratic moods associated with 
dysphoria and agitation should always lead clinicians to 
treat this condition carefully, monitoring suicide risk at 
all time. Antidepressants should be used only after careful 
assessment regarding the absence of such states (Rihmer 
and Akiskal 2006).
Psychiatric inpatients should always be followed-up soon 
after discharge as periods following hospitalization are often 
marked with high suicide risk, especially when patients face 
daily difﬁ  culties and cannot rely on family members or any 
social contact for support (Pompili et al 2005, 2006).
The present study had a number of limitations. The small 
sample size and the lack of information regarding long-term 
pharmacotherapy limit the generalization of the ﬁ  ndings. Neuropsychiatric Disease and Treatment 2008:4(1) 254
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Another limitation is that use of the BHS may have drawbacks 
which are shared by all self-administered psychometric 
instruments. Nevertheless, this simple, self-administered 
method has been reported as an important tool for the 
prediction of suicide (Beck et al 1989). The generalizability 
of our findings is limited by the usual difficulties of a 
retrospective assessment of suicide attempts and the review 
of clinical chart records. Furthermore, suicide attempts 
could not be classiﬁ  ed retrospectively for their potential 
lethality. Finally, our patients had in some cases complex 
treatment regimens, including antidepressants administered 
alone, in combination or as add-on therapy. It could be 
argued that suicidality in these patients was affected by the 
antidepressant treatment. However clear scientiﬁ  c evidence 
supporting this notion is still lacking. One major point 
for further investigation is to take into consideration past 
pharmachological treatment including time and dosage.
In conclusion, we stress the need to better screen MAD 
patients for aggressiveness and impulsivity as well as suicide 
intent. The use of proper pharmacological therapy (especially 
lithium) can dramatically decrease deaths from suicide.
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